Judith W. M. Jeuken - Concepedia

Author

Judith W. M. Jeuken

Also Known As

J. Jeuken, Judith Jeuken, Judith W Jeuken, Judith W M Jeuken, Judith W. Jeuken, Judith W. M. Jeuken, Judith W.M. Jeuken, Judith WM Jeuken, Paul Klinkhamer

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Radboud University Medical Center PAMM Amsterdam UMC Location Vrije Universiteit Amsterdam Canisius-Wilhelmina Ziekenhuis

About

Judith W. M. Jeuken is an author at Radboud University Nijmegen specializing in medicine, pathology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	2K
2	Cell Biology	8	8	583
3	Engineering	3	3	156
4	Health Sciences	3	3	179
5	Biomedical Engineering	1	1	66

Judith W. M. Jeuken

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Christian Hartmann, Jochen Meyer, David Capper, Acta Neuropathologica Neuro-oncologySomatic VariantDiffuse GliomasPathologyNeuroscience	2009	1.1K
<i>MGMT</i> Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951 Martin J. van den Bent, Hendrikus J. Dubbink, Marc Sanson, Journal of Clinical Oncology	2009	253
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone Remco J. Molenaar, Dagmar Verbaan, Simona Lamba, Neuro-Oncology	2014	208
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas Judith W. M. Jeuken, S.J.B. Cornelissen, Martine Vriezen, Laboratory Investigation Semiquantitative DetectionNeuro-oncologyGliomaCancer DetectionMedicine	2007	179
Multiplex Ligation-Dependent Probe Amplification Judith W. M. Jeuken, S.J.B. Cornelissen, Sandra Boots‐Sprenger, Journal of Molecular Diagnostics BioanalysisMolecular BiologyNucleic Acid Amplification TestNucleic Acid AmplificationBiomedical Analysis	2006	126
Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution Sandra Boots‐Sprenger, Angelique Sijben, Jos Rijntjes, Modern Pathology Neuro-oncologySomatic VariantMgmt Promoter MethylationGeneticsMedicine	2013	110
RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations Judith W. M. Jeuken, Caroline Van den Broecke, Sabine Gijsen, Acta Neuropathologica Neuro-oncologyGliomaMedicineRas/raf Pathway ActivationCancer Genomics	2007	108
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy Fabrice Branle, Florence Lefranc, Isabelle Camby, Cancer	2002	106
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization An Claes, Pieter Wesseling, Judith W. M. Jeuken, Molecular Cancer Therapeutics	2008	104
Identification of Subgroups of High-grade Oligodendroglial Tumors by Comparative Genomic Hybridization Judith W. M. Jeuken, Sandra H. E. Sprenger, Pieter Wesseling, Journal of Neuropathology & Experimental Neurology	1999	95

Page 1